Literature DB >> 30225387

Current treatment strategies in pediatric gastrointestinal stromal cell tumor.

Brent A Willobee1, Hallie J Quiroz1, Matthew S Sussman1, Chad M Thorson1, Juan E Sola1, Eduardo A Perez1.   

Abstract

Gastrointestinal stromal tumors (GIST) are exceedingly rare tumors in the pediatric population. As a result, many clinicians either may never see this diagnosis or will encounter it only a few times throughout their careers. Additionally, the more we discover about this disease, it becomes evident that it represents a distinct clinical entity from adult GIST. Many of the treatments and strategies used to combat the adult tumor are either ineffective or may be harmful to the pediatric population with this disease. The unique tumor biology found in pediatric GIST necessitates unique approaches and treatment strategies in order to achieve the best clinical outcome. This review aims to discuss the most recent data available on the different therapeutic modalities utilized in cases of Pediatric GIST.

Entities:  

Keywords:  Pediatric; gastrointestinal stromal tumor (GIST); review; treatment; wild-type (WT)

Year:  2018        PMID: 30225387      PMCID: PMC6131162          DOI: 10.21037/tgh.2018.07.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  42 in total

1.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

2.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Authors:  Dian Wang; Qiang Zhang; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren; Burton L Eisenberg
Journal:  Ann Surg Oncol       Date:  2011-12-28       Impact factor: 5.344

3.  Microscopic margins of resection influence primary gastrointestinal stromal tumor survival.

Authors:  Fausto Catena; Monica Di Battista; Luca Ansaloni; Maria Pantaleo; Pietro Fusaroli; Valerio Di Scioscio; Donatella Santini; Margherita Nannini; Maristella Saponara; Giovanni Ponti; Roberto Persiani; Paolo Delrio; Federico Coccolini; Salomone Di Saverio; Guido Biasco; Daniel Lazzareschi; Antonio Pinna
Journal:  Onkologie       Date:  2012-10-16

4.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors:  Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

5.  Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.

Authors:  Markku Miettinen; Zeng-Feng Wang; Maarit Sarlomo-Rikala; Czeslaw Osuch; Piotr Rutkowski; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

Review 6.  Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

Authors:  Joseph Vadakara; Margaret von Mehren
Journal:  Hematol Oncol Clin North Am       Date:  2013-10       Impact factor: 3.722

7.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

Authors:  Katherine A Janeway; Bernadette Liegl; Amy Harlow; Claudia Le; Antonio Perez-Atayde; Harry Kozakewich; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 8.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

Review 9.  Pediatric/"Wildtype" gastrointestinal stromal tumors.

Authors:  Dhanya Mullassery; Christopher B Weldon
Journal:  Semin Pediatr Surg       Date:  2016-09-04       Impact factor: 2.754

10.  External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.

Authors:  John J Cuaron; Karyn A Goodman; Nancy Lee; Abraham J Wu
Journal:  Radiat Oncol       Date:  2013-11-23       Impact factor: 3.481

View more
  2 in total

Review 1.  Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Authors:  Pushpa Neppala; Sudeep Banerjee; Paul T Fanta; Mayra Yerba; Kevin A Porras; Adam M Burgoyne; Jason K Sicklick
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.